Pembrolizumab has been approved to treat advanced melanoma, advanced PD-L1-positive NSCLC, metastatic urothelial carcinoma (UC), metastatic head and neck squamous-cell carcinoma (HNSCC), hematologic malignancy, microsatellite instability or mismatch repair-deficient cancers, advanced gastroesophageal cancer, metastatic cervical cancer, and locally advanced or metastatic esophageal squamous-cell carcinoma (ESCC) [79]. This evidence concerns the gene CD274 and cancer.